Welcome to Maravai LifeSciences fourth quarter 2024 results earnings call. At this time, all participants are in a ...

If you suffered losses exceeding $50,000 in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like ...

Stifel lowered the firm’s price target on Maravai Lifesciences (MRVI) to $5 from $10 and keeps a Buy rating on the shares. The firm notes Q4 ...

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders acquired 1,002 put options on the stock. This represents ...

Represents additional corporate income taxes at an assumed effective tax rate of approximately 24% applied to additional net loss attributable to Maravai LifeSciences Holdings, Inc. from the ...

2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Maravai LifeSciences Holdings ...

"Our fourth-quarter revenue landed near the midpoint of our guidance range, with the BST segment outperforming and NAP coming in slightly lower," said Trey Martin, CEO, Maravai LifeSciences.

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators ...

Maravai LifeSciences Holdings, Inc.’s MRVI share price has surged by 10.86%, which has investors questioning if this is right time to sell.

"Our fourth-quarter revenue landed near the midpoint of our guidance range, with the BST segment outperforming and NAP coming in slightly lower," said Trey Martin, CEO, Maravai LifeSciences.